Clinical utility of nivolumab in the treatment of advanced melanoma

Clinical utility of nivolumab in the treatment of advanced melanoma

Blog Article

Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic.The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients Wrestling with advanced melanoma.The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall Dog Pack survival in metastatic, refractory melanoma.Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research.

Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies.Keywords: nivolumab, immune checkpoint inhibitors, PD-1, melanoma.